Press release of March 06, 2026
Research team at OncoRay identifies MMP11 as a promising biomarker for liquid biopsy
Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation therapy. Reliable markers that can be used to predict aggressive tumor progression and treatment success at an early stage are still largely lacking. A research team led by Prof. Anna Dubrovska and Dr. Ielizaveta Gorodetska from OncoRay – National Center for Radiation Research in Oncology has now identified a biomarker that can be measured in the blood.
